RecruitingHepatocellular CarcinomaBiliary Tract Cancer
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
Eligible age
18+ yrs
Accepts
All genders
Locations
8 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
GEMINI-Hepatobiliary study will assess the efficacy, safety and tolerability of novel immunomodulators alone and in combination with other anticancer drugs in participants with specified advanced solid tumors.
Sponsor: AstraZeneca
You may qualify if…
- ✓ Age ≥18 years at the time of signing the ICF.
- ✓ Provision of a signed and dated written ICF.
- ✓ Confirmed locally advanced or metastatic solid tumor specified in substudy based on histopathology.
- ✓ Adequate organ and bone marrow function.
- ✓ At least 1 measurable not previously irradiated lesion per RECIST 1.1
- ✓ Life expectancy of at least 12 weeks at the time of screening.
- ✓ Willing and able to provide an adequate tumor sample.
You may not qualify if…
- ✕ History of allogeneic organ transplantation.
- ✕ Active or prior documented autoimmune or inflammatory disorders.
- ✕ Uncontrolled intercurrent illness.
- ✕ History of another primary malignancy, leptomeningeal carcinomatosis, and active primary immunodeficiency.
- ✕ Active infection, brain metastases or spinal cord compression.
- ✕ Participants co-infected with HBV and hepatitis D virus (HDV).
- ✕ Previous treatment in the present study.
- ✕ For substudy 1, history of hepatic encephalopathy within 12 months prior to treatment allocation.
Where it's recruiting
Source: ClinicalTrials.gov · NCT05775159 · last updated 2026-04-17